Objective To systematically assess the application value of vitamin D supplements in the treatment of chronic obstructive pulmonary disease (COPD) to provide evidence-based reference for clinical treatment. Methods The Medline, EM Base, PubMed, Cochrane library, CNKI, VIP database and Wan Fang databases were retrieved by entering the key words. The included randomized controlled trails (RCTs) were performed the literature quality assessment and analyzed by adopting the Rev Man 5.2 software. Results Eleven randomized controlled trials (RCTs) were included, including 1 357 patients. The meta analysis results demonstrated that FEV1% in the observation group was significantly increased compared with the control group, the merge effect size mean difference (MD) of FEV1% (95% CI) was 9.78[7.30, 12.26] with statistical difference (Z=7.73, P<0.01); FEV1/FVC was also increased compared with the control group, the merge effect size MD (95% CI) was 0.09 [1.63, 18.55] with statistical difference (Z=2.34, P=0.02); the CAT scores in the observation group was significantly decreased compared with the control group, the merge effect size MD (95% CI) of CAT score was-5.16 [-5.81, -4.52] with statistical difference (Z=15.78, P<0.00001); the sputum amount in the observation group was decreased compared with the control group,the merge effect size MD (95%) of sputum amount was-6.60 [-7.27, -5.93] with statistical difference (Z=19.39, P<0.01; the serum 25 (OH) D level in the observation group was significantly increased compared with the control group, its merge effect size MD (95% CI) was 13.87 [11.84, 15.90] with statistical difference (Z=13.37, P<0.01). Conclusion Supplementing vitamin D can better improve the pulmonary function and health status, reduces the clinical symptoms and increases the level of serum 25 (OH) D. But due to the limitation of included RCT quality and design methodology, this conclusion needs the large samples and high quality RCT to be further verified. [ABSTRACT FROM AUTHOR]